Bio-economy news

Subscribe to Bio-economy news feed Bio-economy news
Business Wire - The global leader in news distribution
Updated: 9 min 3 sec ago

2018 LifeSciences BC Annual Award Winners Announced

Mon, 19/02/2018 - 18:00
VANCOUVER, British Columbia--(BUSINESS WIRE)--#LSBCAWARDWINNERS--2018 LifeSciences BC Annual Award Winners

World Patient Safety Summit is Sold Out But Space is Available at the Breakout Sessions, Held the Day after the World Summit, at the Royal Society in London

Mon, 19/02/2018 - 09:00
LONDON--(BUSINESS WIRE)--World Patient Safety Summit is Sold Out But Space is Available at the Breakout Sessions, Held the Day After, at the Royal Society in London

OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçet’s Disease with Oral Ulcers

Sat, 17/02/2018 - 17:00
SUMMIT, N.J.--(BUSINESS WIRE)--#AAD18--Celgene Corporation (NASDAQ:CELG) today announced that data from the phase III RELIEF™ clinical trial of OTEZLA® (apremilast) in patients with active Behçet’s Disease with oral ulcers were presented in a late-breaking oral presentation at the 2018 American Academy of Dermatology (AAD) Annual Meeting. The results showed statistically significant reductions in oral ulcers with apremilast 30 mg twice daily (BID) versus placebo through week 12. OTEZLA (apremilast) is

Stallergenes Greer Announces Approval in Japan of Pediatric Use for ACTAIR®, Sublingual Immunotherapy Tablet for the Treatment of House Dust Mite Allergy

Fri, 16/02/2018 - 02:00
LONDON--(BUSINESS WIRE)--Regulatory News: Stallergenes Greer (Paris:STAGR), a biopharmaceutical company specializing in treatments for respiratory allergies, today announced that its partner in Japan, Shionogi & Co. Ltd., received approval for the extension of the indication for ACTAIR®, an allergy immunotherapy sublingual tablet for the treatment of house dust mite (HDM) induced allergic rhinitis, to treat patients under the age of 12. ACTAIR is already approved for the treatment of HDM-in

Takeda Announces Its Certification in Select Group of Global Top Employers® 2018

Thu, 15/02/2018 - 17:00
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO: 4502), (“Takeda”) today announced it has become part of a select group of only thirteen (13) companies and one of two pharmaceuticals to receive global Top Employer® status for 2018. Established over 25 years ago, award certification is given annually by the Top Employers Institute to companies with exceptional employee offerings. The program is organized and designed by the Institute to recognize those that create opt

BIOTECanada Welcomes Federal Government’s $950 Million Superclusters Announcement

Thu, 15/02/2018 - 15:00
OTTAWA, Ontario--(BUSINESS WIRE)--BIOTECanada, the national industry association representing biotechnology companies attended and congratulates the Minister of Innovation, Science and Economic Development and the organizations leading the successful superclusters identified in today’s announcement. The industry is very supportive of all superclusters initiatives including plant-based proteins, digital technology in precision health, AI-powered supply chains, manufacturing and ocean economy. Im

OTEZLA® (Apremilast) Phase II Data Showed Clinically Meaningful Improvements in Patients with Active Ulcerative Colitis

Thu, 15/02/2018 - 10:00
SUMMIT, N.J.--(BUSINESS WIRE)--#ECCOSummit--Celgene Corporation (NASDAQ:CELG) announced that data from a randomized, placebo-controlled, multi-center, phase II clinical trial of apremilast in patients with active ulcerative colitis who had failed at least one conventional therapy but were naïve to biologic therapy were presented in an oral session today at the 13th Congress of ECCO in Vienna (Abstract OP006, 3:30 p.m. CET). The results showed that a higher proportion of patients taking apremilast 30 mg twic

Evotec and MaRS Innovation Announce First Funded Project under LAB150 Bridge

Thu, 15/02/2018 - 03:00
HAMBURG, Germany & TORONTO--(BUSINESS WIRE)--Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and MaRS Innovation announced today that they have identified the first project to be developed under their LAB150 partnership. After signing a collaboration agreement in September 2017, the first project within this academic BRIDGE has now been identified. The project aims to develop kallikrein-targeting compounds as novel topical drugs for the rare but severe inflammatory skin di

The New England Journal of Medicine Publishes SPINRAZA® (nusinersen) Phase 3 Study Results in Individuals with Later-Onset Spinal Muscular Atrophy

Wed, 14/02/2018 - 18:00
CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)--The New England Journal of Medicine Publishes SPINRAZA® (nusinersen) Phase 3 Study Results in Individuals with Later-Onset Spinal Muscular Atrophy

FDA Grants Marketing Authorization to Banyan Biomarkers for the First Diagnostic Blood Test for Traumatic Brain Injury

Wed, 14/02/2018 - 15:00
SAN DIEGO--(BUSINESS WIRE)--Banyan BTI is the first in vitro diagnostic blood test to aid in the evaluation of patients with suspected TBI, also known as concussion.

Lattice Biologics Ltd. Announces Management Cease Trade Order

Wed, 14/02/2018 - 10:00
BELGRADE, Mont.--(BUSINESS WIRE)--Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBLTF) (“Lattice Biologics” or the “Company”) is providing this default status report in accordance with National Policy 12-203 – Management Cease Trade Orders. The Company’s audited annual financial statements, related management’s discussion and analysis and accompanying CEO and CFO certifications for the financial year ended September 30, 2017 (collectively, the “Required Filings”) would not be completed by the pre

Aurinia Pharmaceuticals Launches New Lupus Nephritis Disease Awareness Program

Wed, 14/02/2018 - 09:00
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that it has launched ALL INTM, an educational program for people living with lupus nephritis (LN). ALL IN is designed to raise awareness for LN and to support members of the LN community. LN in an inflammation of the kidney caused by Systemic Lupus Erythematosus (SLE) and

Ferring Announces 30 Million CHF Investment in New Biotech Centre in Switzerland

Wed, 14/02/2018 - 07:00
SAINT-PREX, Switzerland--(BUSINESS WIRE)--Ferring Pharmaceuticals announced today that it is expanding its capabilities in biologics through a new biotech centre which will be installed at the company’s existing headquarters and manufacturing site in Saint-Prex, Switzerland. Over the next three years, Ferring will invest approximately 30 million CHF in the new Ferring Biotech Centre, which will incorporate discovery and development capabilities for monoclonal antibodies as well as biologics man

New Genome Study of B. longum subsp. longum by Morinaga Milk May Explain the Species' Wide Distribution across All Ages

Wed, 14/02/2018 - 06:00
TOKYO--(BUSINESS WIRE)--Morinaga Milk Industry announced results of a groundbreaking genome study on B. longum to explain the species' wide distribution across all ages

Celltrion Receives EU Approval for Trastuzumab Biosimilar

Tue, 13/02/2018 - 21:00
INCHEON, South Korea--(BUSINESS WIRE)--#AnticancerMonoclonalAntibody--Celltrion's Herzuma® (trastuzumab biosimilar) receives EU approval for early breast cancer, metastatic breast cancer, and metastatic gastric cancer.

World Patient Safety Summit Aims to Reduce Unnecessary C-Sections

Tue, 13/02/2018 - 13:00
LONDON--(BUSINESS WIRE)--World Patient Safety Summit Aims to Reduce Unnecessary C-Sections – researchers say that nearly half are unnecessary and pose serious risks

DiaCarta, Ltd Raises $45 Million USD Series B Funding to Expand Its Liquid Biopsy Cancer Detection Platform & Services

Mon, 12/02/2018 - 09:00
RICHMOND, Calif.--(BUSINESS WIRE)--DiaCarta, the precision molecular diagnostics company, has announced that it has completed its Series B funding round, realizing a total of $45.0M USD

Bloom Burton & Co. Announces the 2018 Bloom Burton Award Gala

Mon, 12/02/2018 - 09:00
TORONTO--(BUSINESS WIRE)--Bloom Burton & Co. (“Bloom Burton”) is thrilled to announce the 2018 Bloom Burton Award Gala, to be held at the Four Seasons Hotel in Toronto, Ontario, Canada on Thursday, September 27, 2018. Bestowed annually, the Bloom Burton Award honours an individual scientist, inventor, executive, entrepreneur, industry leader, or policy maker who made the greatest contribution to Canada’s innovative healthcare industry in the previous year. Nominees will be accepted from any

Covalon Announces Strong First Quarter Financial Results

Mon, 12/02/2018 - 08:00
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, announced today its first quarter financial results. First Quarter Summary Financial Results Revenue for the three months ended December 31, 2017 was $6,404,705. Gross margin for the quarter ended December 31, 2017 was 71%. Net income for the quarter was $523,345 or $0.02 per share. CEO Comment Mr. Brian Pedlar, Covalon President and

Covalon Announces Conference Call to Discuss Q1 Financial Results

Fri, 09/02/2018 - 09:00
MISSISSAUGA, Ontario--(BUSINESS WIRE)--#Q1--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, has scheduled a conference call to be held Tuesday February 13th 2018 at 9:00 a.m. EST, to discuss the financial results of the first quarter ended December 31st 2017. The Company intends to release its Q1 financial results on Monday February 12th 2018. To participate in the live call, please dial: Local / International: 647-792-1278North American

Pages